Drug Trial Radar · NCT06936527
XS-03 in Combination With FOLFOX or FOLFIRI and Bevacizumab for Treatment of Metastatic Colorectal Cancer Patients With RAS Mutation
Last checked: Nov 19, 2026Latest source record: Sep 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Enrolling by invitation
Enrollment
102
Planned (sponsor's estimate)
Start
May 23, 2025
Primary completion
Apr 30, 2028
Study completion Jul 30, 2028
Sponsor
- Lead sponsor
- Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.Industry
- Sponsor type
- Industry
- First posted
- Apr 20, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
XS-03 in combination with FOLFOX or FOLFIRI and Bevacizumab for treatment of metastatic colorectal cancer patients with RAS mutation
Conditions
- Colorectal Cancer
- Metastatic Colorectal Cancer With RAS Mutation
Interventions
Drug: XS-03, Biological: Bevacizumab, Drug: FOLFOX, Drug: FOLFIRIBiological
XS-03 orally Bevacizumab intravenously FOLFOX intravenously FOLFIRI intravenously
Drug: XS-03Biological
XS-03 orally
Biological: Bevacizumab, Drug: FOLFOX, Drug: FOLFIRIBiological
Bevacizumab intravenously FOLFOX intravenously FOLFIRI intravenously
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 1b: Number of participants with Dose-limiting Toxicities (DLTs) in experimental arm of XS-03 in combination with FOLFOX or FOLFIRI and BevacizumabTime frame: up to day 28
- Phase 1b: Determine the Maximum Tolerated Dose (MTD) in experimental arm of XS-03 in combination with FOLFOX or FOLFIRI and BevacizumabTime frame: up to day 28
- Phase 2: Objective Response Rate (ORR) of two experimental arms and comparator armTime frame: up to 18 months after first dose of last patient
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Beijing Cancer Hospital
Beijing, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.